Physician profile
Jared Martin
NPI 1659860724
$1,800.77
in general payments reported to CMS, 2019-2025
23 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $531 · 2022: $65.34 · 2023: $334 · 2024: $610 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,204.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $326.58 | 2021-2024 | Caplyta |
| Abbvie INC. | $241.74 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $216.35 | 2021-2023 | Ingrezza |
| Abbott Laboratories | $173.11 | 2025 | Aveir |
| Otsuka America Pharmaceutical, INC. | $123.61 | 2021-2022 | |
| Amgen INC. | $110.94 | 2024 | Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $87.04 | 2025 | |
| Alkermes, INC. | $85.12 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $76.01 | 2023-2024 | Airsupra, Breztri, Farxiga |
| Vanda Pharmaceuticals INC. | $55.38 | 2021 | |
| Lilly USA, LLC | $47.20 | 2024 | Mounjaro, Zepbound, Jardiance |
| Tersera Therapeutics LLC | $32.05 | 2023 | Quzyttir |
| Janssen Pharmaceuticals, INC | $31.00 | 2021 | |
| Lundbeck LLC | $27.12 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $23.23 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $22.99 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $22.07 | 2024 | |
| Mylan Specialty L.P. | $20.80 | 2023 | Yupelri |
| Eisai INC. | $19.58 | 2021 | |
| Nevro Corp. | $16.86 | 2024 | Senza |
| Takeda Pharmaceuticals U.S.A., INC. | $15.83 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.22 | 2021 | |
| Ironshore Pharmaceuticals INC. | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.